GSK ex-vaccines chief says group’s blockbuster flu jab is too …
WEB9 hours ago · GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn and winter is too expensive and difficult to use after raising $100mn for a rival start-up to ...
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
WEB5 days ago · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push
WEBSep 13, 2024 · Global News Select GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push Provided by Dow Jones. Sep 13, 2024 4:40pm ... GSK's revenue last year stood at 30.33 billion pounds ($39.80 billion ...
GSK Announces Positive Topline Data on Co-Administration of …
WEB5 days ago · PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with …
GSK antibody drug reduces COPD attacks in trial
WEBSep 6, 2024 · Dive Brief: GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive pulmonary disease, offering the British drugmaker another shot at an expanded approval for the drug. The trial, known as MATINEE, included COPD patients suffering from chronic bronchitis and/or emphysema who were already …
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
GSK Announces FDA Acceptance of New Meningococcal Jab BLA - Yahoo Finance
WEBApr 17, 2024 · The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
GSK shares fall as US narrows age recommendation for RSV vaccines
WEBJun 27, 2024 · GSK shares fell more than 6 per cent on Thursday morning after US health officials recommended restricting the use of vaccines for respiratory syncytial virus, an area in which the British ...
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
Skip to content